# NF-κB Pathway: Activation, Regulation, and Role in Disease

## Introduction to the NF-κB Pathway

### What is NF-κB?

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a family of inducible [transcription factors](/knowledge/molecular-biology/transcription-factor) that control the expression of hundreds of genes involved in inflammation, innate and adaptive immunity, [cell proliferation](/blog/guides/cell-proliferation), apoptosis, and stress responses. NF-κB proteins exist in the cytoplasm of most resting cells in an inactive form, sequestered by inhibitor proteins. Upon receiving an appropriate extracellular signal, NF-κB rapidly translocates to the nucleus, binds specific DNA sequences called κB sites (consensus: 5′-GGGRNNYYCC-3′, where R is purine, Y is pyrimidine, and N is any nucleotide), and drives transcriptional programs that shape cellular responses to infection, injury, and stress.

The name derives from its original discovery as a nuclear factor that binds to the kappa light-chain enhancer in B lymphocytes. However, NF-κB is now recognized as a ubiquitous, evolutionarily conserved signaling hub that operates in virtually all cell types. Its activation is fast—typically occurring within minutes of stimulation—because it does not require new protein synthesis. This speed makes NF-κB a first-responder [transcription factor](/knowledge/molecular-biology/transcription-factor), ideally suited for coordinating immediate cellular defenses.

### Historical context

NF-κB was discovered in 1986 by David Baltimore and Ranjan Sen while studying the regulation of immunoglobulin kappa light-chain gene expression in B cells. They identified a nuclear protein that bound specifically to a 10-base-pair sequence in the kappa light-chain enhancer, and named it NF-κB. Subsequent work by Michael Karin, Inder Verma, and others revealed that NF-κB is not B-cell-specific but is present in the cytoplasm of nearly all mammalian cells, held inactive by IκB inhibitors. The cloning of the p65 (RelA) and p50 subunits in the early 1990s, followed by the identification of the IκB kinase (IKK) complex in 1997, established the core framework of the signaling pathway. The field has since expanded to encompass more than 500 target genes, multiple activating stimuli, and a complex regulatory network that includes post-translational modifications, cross-talk with other signaling cascades, and context-dependent transcriptional outcomes.

## Components of the NF-κB Family

### NF-κB proteins

The mammalian NF-κB family comprises five proteins that share a conserved N-terminal Rel homology domain (RHD) of approximately 300 amino acids. The RHD mediates three critical functions: DNA binding, dimerization, and nuclear localization. Within the RHD, a nuclear localization sequence (NLS) is normally masked by IκB binding in resting cells.

The five family members are:

| Protein | Gene | Structure | Key Features |
|---------|------|-----------|--------------|
| p65 (RelA) | RELA | RHD + C-terminal transactivation domain (TAD) | Major transcriptional activator; contains TAD |
| RelB | RELB | RHD + TAD | Activates genes in non-canonical pathway; lacks IκB-binding domain |
| c-Rel | REL | RHD + TAD | Important in lymphocytes; contains TAD |
| p105/p50 | NFKB1 | RHD only (p50); p105 is precursor | p50 lacks TAD; processed from p105 |
| p100/p52 | NFKB2 | RHD only (p52); p100 is precursor | p52 lacks TAD; processed from p100 |

p50 and p52 are generated by proteolytic processing of their longer precursors, p105 and p100, respectively. Because p50 and p52 lack transactivation domains, homodimers of these proteins often repress transcription unless they associate with co-activators. The transcriptionally active forms are typically heterodimers containing p65, RelB, or c-Rel. The most abundant and best-studied form is the p65/p50 heterodimer, which drives the canonical pathway.

### IκB proteins

The inhibitor of NF-κB (IκB) family sequesters NF-κB dimers in the cytoplasm. The classical IκB proteins include IκBα (encoded by NFKBIA), IκBβ (NFKBIB), and IκBε (NFKBIE). These proteins contain multiple ankyrin repeat domains that bind the RHD of NF-κB, masking the NLS and preventing nuclear entry. IκBα is the best characterized: it binds p65/p50 heterodimers, and its degradation is the central event in canonical activation.

Two additional proteins, p105 and p100, also function as IκB-like molecules. The C-terminal halves of these precursors contain ankyrin repeats that inhibit the associated RHD. Thus, p105 and p100 serve dual roles as both NF-κB subunits and IκB proteins. This dual function is exploited in the non-canonical pathway, where p100 processing to p52 releases active NF-κB complexes.

## Canonical NF-κB Activation Pathway

### Stimuli and receptors

The canonical pathway is triggered by a broad range of stimuli, including pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), bacterial lipopolysaccharide (LPS), viral double-stranded RNA, antigen receptor engagement, and genotoxic stress. These stimuli engage distinct receptor systems that converge on the IKK complex.

TNF-α binds tumor necrosis factor receptor 1 (TNFR1), a death receptor that recruits the adaptor protein TRADD (TNFR1-associated death domain protein). TRADD then recruits TRAF2 (TNF receptor-associated factor 2) and RIPK1 (receptor-interacting serine/threonine-protein kinase 1). RIPK1 undergoes polyubiquitination, which serves as a scaffold for the recruitment of the IKK complex and the TAK1 kinase complex.

IL-1β binds the IL-1 receptor (IL-1R), which recruits the adaptor MyD88, the kinase IRAK4, and TRAF6. TRAF6, like RIPK1, becomes polyubiquitinated with K63-linked ubiquitin chains, providing a platform for TAK1 and IKK recruitment. LPS signals through Toll-like receptor 4 (TLR4) using a similar MyD88-dependent pathway.

### IKK complex activation

The IKK complex is a high-molecular-weight (~700–900 kDa) complex composed of three subunits: IKKα (CHUK), IKKβ (IKBKB), and NEMO (NF-κB essential modulator, also called IKKγ, encoded by IKBKG). IKKα and IKKβ are catalytic serine/threonine kinases, while NEMO is a regulatory scaffold protein that is essential for canonical signaling.

Activation of the IKK complex requires phosphorylation of the activation loop of IKKβ at serines 177 and 181. This phosphorylation is carried out by TAK1 (TGF-β-activated kinase 1), which is recruited to the ubiquitinated signaling complexes described above. TAK1 also phosphorylates and activates MAP kinases, linking NF-κB activation to the [MAPK Pathway](/knowledge/molecular-biology/mapk-pathway). NEMO itself is modified by ubiquitination and phosphorylation, which stabilizes the complex and promotes its activation.

The IKK complex phosphorylates IκBα at serines 32 and 36. This phosphorylation is highly specific: IKKβ recognizes the consensus sequence DS*GXXS*, where S* denotes the phosphorylated serines. IKKα can also phosphorylate IκBα but is less efficient; in the canonical pathway, IKKβ is the primary kinase.

### IκB phosphorylation and degradation

Once IκBα is phosphorylated at S32 and S36, it is recognized by the E3 ubiquitin ligase SCFβ-TrCP (Skp1-Cul1-F-box protein β-transducin repeat-containing protein). This ligase conjugates K48-linked polyubiquitin chains to lysines 21 and 22 of IκBα. Polyubiquitinated IκBα is then rapidly degraded by the 26S proteasome.

The degradation of IκBα exposes the NLS of the p65/p50 heterodimer, allowing it to translocate into the nucleus. In the nucleus, NF-κB binds κB sites in the promoters and enhancers of target genes. The entire process—from receptor engagement to nuclear translocation—takes approximately 10–30 minutes.

A key feature of the canonical pathway is its oscillatory behavior. Because NF-κB activates transcription of NFKBIA (encoding IκBα), newly synthesized IκBα enters the nucleus, removes NF-κB from DNA, and exports it back to the cytoplasm. This negative feedback loop produces damped oscillations in NF-κB nuclear localization, with a period of approximately 100 minutes. The amplitude and frequency of these oscillations can influence which target genes are expressed.

## Non-Canonical NF-κB Activation Pathway

### Stimuli and receptors

The non-canonical pathway operates more slowly (hours rather than minutes) and is activated by a narrower set of stimuli. These include members of the TNF superfamily: lymphotoxin-β (LTβ), B-cell activating factor (BAFF), CD40 ligand (CD40L), and receptor activator of NF-κB ligand (RANKL). These stimuli engage receptors such as LTβR, BAFF-R, CD40, and RANK, which recruit TRAF2 and TRAF3.

A critical distinction is that the non-canonical pathway does not require NEMO or IKKβ. Instead, it depends on NF-κB-inducing kinase (NIK, encoded by MAP3K14) and IKKα homodimers.

### NIK and IKKα

In resting cells, NIK is constitutively degraded by a complex containing TRAF2, TRAF3, and the E3 ubiquitin ligases cIAP1 and cIAP2 (cellular inhibitor of apoptosis proteins). These ligases conjugate K48-linked ubiquitin chains on NIK, targeting it for proteasomal degradation. This keeps NIK protein levels very low.

Upon receptor stimulation, TRAF2 and TRAF3 are recruited to the receptor and subsequently degraded. cIAP1/2, which are also recruited, undergo autoubiquitination and degradation. The loss of TRAF2/TRAF3/cIAP1/2 stabilizes NIK, allowing it to accumulate. Newly synthesized NIK then phosphorylates and activates IKKα homodimers.

### p100 processing

The activated IKKα phosphorylates p100 at two C-terminal serine residues (S866 and S870 in humans). This phosphorylation creates a binding site for SCFβ-TrCP, which ubiquitinates p100 on lysine residues near the C-terminus. The ubiquitinated p100 is then partially degraded by the proteasome, removing the C-terminal IκB-like domain and generating the mature p52 subunit.

The processing of p100 to p52 releases RelB/p52 heterodimers, which translocate to the nucleus and activate target genes. RelB is the preferred partner for p52; the non-canonical pathway therefore primarily activates RelB/p52 complexes, in contrast to the p65/p50 complexes of the canonical pathway.

The non-canonical pathway is essential for B-cell survival and maturation, secondary lymphoid organ development (including lymph nodes and Peyer's patches), and humoral immune responses. Defects in this pathway cause immunodeficiency and impaired lymphoid organogenesis.

## Regulation of NF-κB Signaling

### Negative feedback

NF-κB signaling is tightly controlled by multiple negative feedback mechanisms that prevent excessive or prolonged inflammation. The most immediate is IκBα resynthesis. NF-κB target genes include NFKBIA, NFKBIB, and NFKBIE. Newly synthesized IκBα enters the nucleus, strips NF-κB from DNA, and exports it to the cytoplasm. This creates the oscillatory dynamics described earlier and terminates the transcriptional response.

A second major negative regulator is A20 (encoded by TNFAIP3). A20 is a deubiquitinase and E3 ligase that removes K63-linked ubiquitin chains from RIPK1 and TRAF6, thereby disassembling the signaling complexes that activate IKK. A20 also adds K48-linked ubiquitin chains to RIPK1, promoting its degradation. A20 is itself an NF-κB target gene, creating another feedback loop. Loss of A20 function causes severe inflammatory pathology in humans and mice.

Other deubiquitinases, including CYLD and OTUB1, also negatively regulate NF-κB by removing activating ubiquitin chains from upstream signaling molecules. CYLD is particularly important in T cells and is mutated in familial cylindromatosis, a skin tumor syndrome.

### Post-translational modifications

NF-κB subunits themselves are subject to extensive post-translational modification that modulates their activity. Phosphorylation of p65 at serine 536 by IKKβ or other kinases enhances its transcriptional activity. Phosphorylation at serine 276 by protein kinase A (PKA) promotes recruitment of the co-activator CBP/p300. Acetylation of p65 at lysine 310 also enhances transcriptional activity, while deacetylation by HDAC3 attenuates it.

Ubiquitination of NF-κB subunits can target them for degradation or alter their function. For example, ubiquitination of p65 at K195 and K315 by the E3 ligase PDLIM2 targets it for proteasomal degradation, terminating the response. Methylation of p65 at K314 and K315 by the methyltransferase SETD6 represses its activity.

These modifications allow fine-tuning of NF-κB responses in a cell-type- and stimulus-specific manner. They also provide potential therapeutic targets, as modulating p65 phosphorylation or acetylation could selectively inhibit pathogenic NF-κB activity without blocking all NF-κB functions.

## NF-κB Target Genes and Biological Functions

### Inflammatory cytokines

NF-κB is the master regulator of the inflammatory response. It directly activates transcription of genes encoding pro-inflammatory cytokines, including TNF-α (TNF), IL-1β (IL1B), IL-6 (IL6), and IL-8 (CXCL8). These cytokines recruit immune cells to sites of infection, induce fever, and activate the acute-phase response. NF-κB also induces expression of cyclooxygenase-2 (COX2, encoded by PTGS2) and inducible nitric oxide synthase (iNOS, encoded by NOS2), which produce prostaglandins and nitric oxide, respectively, amplifying inflammation.

The induction of TNF-α is particularly significant because TNF-α can itself activate NF-κB, creating a positive feedback loop that amplifies inflammation. This loop is normally controlled by the negative regulators described above, but when these fail, [chronic inflammation](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/chronic-inflammation-causes-and-morphologic-features) ensues.

### Anti-apoptotic factors

NF-κB promotes cell survival by inducing expression of anti-apoptotic proteins. Key targets include c-FLIP (CFLAR), which inhibits caspase-8 activation; Bcl-2 family members such as Bcl-xL (BCL2L1) and A1/Bfl-1 (BCL2A1); and inhibitors of apoptosis proteins (IAPs) such as cIAP1 (BIRC2), cIAP2 (BIRC3), and XIAP (XIAP). These proteins block both the extrinsic and intrinsic [Apoptosis Pathway](/knowledge/molecular-biology/apoptosis-pathway).

This pro-survival function explains why NF-κB activation often protects cells from TNF-induced apoptosis. In fact, TNF-α simultaneously activates both NF-κB (pro-survival) and caspase-8 (pro-apoptotic) signals; the balance between these determines cell fate. Cells with defective NF-κB signaling are highly sensitive to TNF-induced killing.

### Immune receptors

NF-κB induces expression of numerous immune receptors and co-stimulatory molecules. These include major histocompatibility complex (MHC) class I and class II molecules, which present antigens to T cells; the co-stimulatory molecules CD80 and CD86 on antigen-presenting cells; and the IL-2 receptor alpha chain (CD25), which is essential for T-[cell proliferation](/blog/guides/cell-proliferation). NF-κB also regulates expression of adhesion molecules such as ICAM-1 (ICAM1) and VCAM-1 (VCAM1), which mediate leukocyte extravasation into inflamed tissues.

In B cells, NF-κB induces expression of the survival factor BAFF-R and the chemokine receptor CXCR5, both required for B-cell maturation and migration. The non-canonical pathway is particularly important for these B-cell functions.

## Methods to Study the NF-κB Pathway

### Reporter gene assays

The most common method to measure NF-κB transcriptional activity is the [luciferase reporter assay](/knowledge/diagnostics/molecular/luciferase-reporter-assay). Cells are transfected with a plasmid containing the firefly luciferase gene under the control of a minimal promoter with tandem NF-κB binding sites (typically 3–5 copies of the κB consensus sequence). After stimulation, cells are lysed and luciferase activity is measured using a luminometer. The assay is quantitative, sensitive, and amenable to high-throughput screening.

A more sophisticated variant uses a destabilized luciferase with a short half-life, allowing real-time measurement of NF-κB activity in living cells. Alternatively, a secreted luciferase (e.g., NanoLuc) can be measured in culture medium, enabling kinetic studies without cell lysis.

### Protein analysis

Western blotting is used to monitor the key events of NF-κB activation. The most informative readouts include:

1. **IκBα degradation**: Blot for IκBα at 0, 5, 15, 30, and 60 minutes after stimulation. A decrease at 5–15 minutes followed by resynthesis at 30–60 minutes confirms canonical activation.
2. **Phospho-IκBα**: Use an antibody specific for phospho-S32/S36 IκBα. This appears transiently before degradation.
3. **Phospho-p65**: Antibodies against phospho-S536 p65 report IKK activity.
4. **p100/p52 processing**: In the non-canonical pathway, blot for p100 (higher molecular weight) and p52 (lower molecular weight). Increased p52/p100 ratio indicates activation.

For nuclear translocation, prepare cytoplasmic and nuclear fractions and blot for p65 in each. Alternatively, use [immunofluorescence microscopy](/blog/guides/immunofluorescence-microscopy-controls-for-specific-and-reproducible-images) with anti-p65 antibodies; in resting cells, p65 is cytoplasmic, while after stimulation it accumulates in the nucleus.

### Genetic models

Knockout mice have been generated for most NF-κB family members and regulators. RelA (p65) knockout mice die embryonically at day 15 due to massive liver apoptosis, demonstrating the essential pro-survival role of NF-κB. IKKβ knockout mice also die embryonically with similar liver degeneration. NEMO knockout mice die embryonically, while NEMO mutations in humans cause incontinentia pigmenti, an X-linked disorder.

NFKB1 (p105/p50) knockout mice are viable but have defects in B-cell function and basal immunoglobulin production. NFKB2 (p100/p52) knockout mice lack lymph nodes and Peyer's patches, confirming the role of the non-canonical pathway in lymphoid organogenesis.

For cell-type-specific studies, conditional knockout mice using the Cre-loxP system are widely used. For example, mice with IKKβ deleted specifically in intestinal epithelial cells show increased susceptibility to colitis and colorectal cancer, illustrating the tissue-specific functions of NF-κB.

## NF-κB in Disease and Therapeutic Targeting

### Cancer

NF-κB is constitutively activated in many human cancers, including multiple myeloma, Hodgkin lymphoma, breast cancer, colorectal cancer, and pancreatic cancer. This constitutive activation promotes tumor cell survival, proliferation, angiogenesis, and metastasis. The mechanisms of constitutive activation include:

- Mutations in upstream regulators (e.g., loss of A20 in lymphomas)
- Autocrine cytokine loops (e.g., TNF-α or IL-6 produced by tumor cells)
- Chronic inflammation in the tumor microenvironment
- Mutations in NFKB2 or NFKB1 themselves

The pro-survival function of NF-κB is particularly important in cancer because it allows tumor cells to resist apoptosis induced by chemotherapy and radiation. NF-κB also induces expression of matrix metalloproteinases (MMPs) that degrade extracellular matrix and promote invasion, and of vascular endothelial growth factor (VEGF) that drives angiogenesis.

The connection between inflammation and cancer is well established: chronic inflammatory conditions such as ulcerative colitis, hepatitis B/C, and Helicobacter pylori gastritis markedly increase cancer risk, largely through NF-κB activation. This links NF-κB to the [P53 Pathway](/knowledge/molecular-biology/p53-pathway), as NF-κB and p53 often have opposing effects on cell survival.

### Inflammatory diseases

Chronic NF-κB activation underlies numerous inflammatory and autoimmune diseases. In rheumatoid arthritis, NF-κB drives production of TNF-α, IL-6, and IL-1β in the synovium, promoting joint destruction. Inflammatory bowel disease (Crohn's disease and ulcerative colitis) is associated with elevated NF-κB activity in intestinal macrophages and epithelial cells. Asthma, psoriasis, and atherosclerosis also feature prominent NF-κB activation.

The central role of NF-κB in these diseases is underscored by the efficacy of anti-TNF-α biologics (e.g., infliximab, adalimumab) in treating rheumatoid arthritis and inflammatory bowel disease. These drugs block the TNF-α/NF-κB axis, reducing inflammation and tissue damage.

### Therapeutic strategies

Several approaches to inhibit NF-κB are in development or clinical use:

1. **Proteasome inhibitors**: Bortezomib (Velcade) blocks IκBα degradation by inhibiting the proteasome, thereby preventing NF-κB nuclear translocation. It is approved for multiple myeloma and mantle cell lymphoma. However, proteasome inhibition affects many other pathways, causing significant toxicity.

2. **IKK inhibitors**: Small-molecule inhibitors of IKKβ (e.g., BMS-345541, MLN120B) have shown efficacy in preclinical models of inflammation and cancer. None are yet approved clinically, partly due to on-target toxicity from prolonged NF-κB blockade.

3. **Anti-cytokine biologics**: Antibodies against TNF-α, IL-6 receptor (tocilizumab), and IL-1β (canakinumab) block upstream activators of NF-κB. These are highly effective in autoimmune diseases.

4. **NEMO-binding domain (NBD) peptides**: Cell-permeable peptides that disrupt NEMO-IKKβ interaction selectively inhibit canonical NF-κB without affecting IKKα-dependent functions. These are in preclinical development.

5. **Natural compounds**: Curcumin, resveratrol, and parthenolide inhibit NF-κB at various levels, though their specificity and bioavailability are limited.

A major challenge is that NF-κB is essential for normal immune function; complete inhibition causes immunosuppression. Therefore, therapeutic strategies aim to selectively inhibit pathological NF-κB activity while preserving protective functions. This might be achieved by targeting specific upstream kinases, specific NF-κB dimers, or tissue-specific regulators.

## Common Pitfalls and Misconceptions

### Pathway confusion

A frequent student error is conflating the canonical and non-canonical pathways. Remember these key distinctions:

| Feature | Canonical | Non-canonical |
|---------|-----------|---------------|
| Kinases | IKKβ + NEMO | IKKα homodimers |
| Upstream kinase | TAK1 | NIK |
| Inhibitor degraded | IκBα | p100 (processed to p52) |
| Active dimer | p65/p50 | RelB/p52 |
| Time course | Minutes | Hours |
| Major stimuli | TNF-α, IL-1β, LPS | LTβ, BAFF, CD40L |
| NEMO required? | Yes | No |

Another common error is assuming that IKKα is redundant with IKKβ. In the canonical pathway, IKKβ is the essential kinase; IKKα plays a minor role. In the non-canonical pathway, IKKα is essential and IKKβ is dispensable.

### Overlooking negative regulation

Students often focus on activation and forget that NF-κB signaling is inherently self-limiting. The pathway is not simply "on" or "off"—it produces oscillatory dynamics due to IκBα feedback. When interpreting experimental data, remember that IκBα levels at 60 minutes post-stimulation may be higher than at baseline due to resynthesis. A common mistake is to conclude that NF-κB is not activated because IκBα is not degraded at a late time point; the degradation is transient.

### Experimental artifacts

Several technical pitfalls can confound NF-κB experiments:

1. **Serum starvation**: Many protocols starve cells of serum before stimulation. However, serum contains growth factors that activate NF-κB; serum removal itself can cause stress responses. Always include appropriate controls.

2. **LPS contamination**: Recombinant proteins and plasmid preparations can be contaminated with LPS, which activates NF-κB through TLR4. Use polymyxin B or endotoxin-free reagents when studying other stimuli.

3. **Overexpression artifacts**: Transfecting high amounts of NF-κB or IKK expression plasmids can cause spontaneous activation due to overexpression-induced aggregation or autophosphorylation. Use low DNA amounts and include empty-vector controls.

4. **Antibody specificity**: Phospho-specific antibodies can cross-react with unphosphorylated proteins or with phosphorylated forms of related proteins. Validate antibodies by treating samples with lambda phosphatase or using knockout lysates.

5. **Timing**: NF-κB responses are rapid. If you harvest cells 2 hours after TNF-α stimulation, you may miss the peak of IκBα degradation and p65 nuclear translocation. For canonical pathway studies, harvest at 5–30 minutes.

## Frequently Asked Questions

### What is the NF-κB pathway?

The NF-κB pathway is a [signal transduction](/knowledge/molecular-biology/signal-transduction) cascade that controls the activity of NF-κB transcription factors. In resting cells, NF-κB is held inactive in the cytoplasm by IκB inhibitor proteins. Upon stimulation by cytokines, pathogens, or stress, a kinase cascade leads to IκB phosphorylation and degradation, allowing NF-κB to enter the nucleus and activate target genes involved in inflammation, immunity, and cell survival.

### What does NF-κB stand for?

NF-κB stands for Nuclear Factor kappa-light-chain-enhancer of activated B cells. The name reflects its discovery as a nuclear factor that binds the kappa light-chain immunoglobulin enhancer in B lymphocytes. The "kappa" refers to the kappa light chain of antibodies, not to the Greek letter kappa in the DNA sequence.

### What are the main steps of the canonical NF-κB pathway?

The canonical pathway proceeds through five main steps: (1) ligand binding to receptors such as TNFR1 or TLR4 recruits adaptor proteins and ubiquitin ligases; (2) TAK1 is activated and phosphorylates IKKβ at S177/S181; (3) activated IKKβ phosphorylates IκBα at S32/S36; (4) phosphorylated IκBα is ubiquitinated by SCFβ-TrCP and degraded by the proteasome; (5) freed p65/p50 heterodimers translocate to the nucleus and activate target gene transcription.

### What is the difference between canonical and non-canonical NF-κB pathways?

The canonical pathway is triggered by pro-inflammatory stimuli, requires IKKβ and NEMO, degrades IκBα, and activates p65/p50 dimers within minutes. The non-canonical pathway is triggered by specific TNF superfamily ligands, requires NIK and IKKα, processes p100 to p52, and activates RelB/p52 dimers over hours. The canonical pathway operates in most cells, while the non-canonical pathway is mainly important in B cells and lymphoid tissue development.

### What activates the NF-κB pathway?

NF-κB is activated by a diverse range of stimuli, including pro-inflammatory cytokines (TNF-α, IL-1β), bacterial components (LPS), viral products (double-stranded RNA), DNA damage, oxidative stress, and antigen receptor engagement. These stimuli converge on the IKK complex, which is the central integrator of NF-κB activation signals.

### What is the role of NF-κB in inflammation?

NF-κB is the master transcription factor of inflammation. It induces expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), chemokines (IL-8), adhesion molecules (ICAM-1, VCAM-1), and inflammatory enzymes (COX-2, iNOS). These mediators recruit immune cells, increase vascular permeability, and coordinate the acute inflammatory response. When NF-κB regulation fails, chronic inflammation develops.

### How is NF-κB regulated?

NF-κB is regulated at multiple levels: (1) cytoplasmic sequestration by IκB proteins; (2) IKK-dependent phosphorylation and degradation of IκB; (3) negative feedback through IκB resynthesis; (4) deubiquitinases such as A20 and CYLD that disassemble activating complexes; (5) post-translational modifications of NF-κB subunits including phosphorylation, acetylation, and ubiquitination; and (6) cross-talk with other signaling pathways such as the [JAK STAT Pathway](/knowledge/molecular-biology/jak-stat-pathway) and [PI3K AKT Pathway](/knowledge/molecular-biology/pi3k-akt-pathway).

### Why is NF-κB important in cancer?

NF-κB promotes cancer through several mechanisms: it induces anti-apoptotic proteins that make tumor cells resistant to cell death; it drives expression of growth factors and their receptors; it promotes angiogenesis through VEGF; it activates matrix metalloproteinases that facilitate invasion and metastasis; and it creates an inflammatory microenvironment that supports tumor progression. Constitutive NF-κB activation is found in many cancers and is associated with poor prognosis.

## Key Takeaways

- NF-κB is a family of five transcription factors (p65, RelB, c-Rel, p50, p52) that regulate hundreds of genes involved in inflammation, immunity, and cell survival.
- The canonical pathway is triggered by pro-inflammatory stimuli, requires IKKβ and NEMO, and activates p65/p50 dimers through IκBα degradation.
- The non-canonical pathway is triggered by TNF superfamily ligands, requires NIK and IKKα, and activates RelB/p52 dimers through p100 processing.
- NF-κB signaling is tightly regulated by negative feedback loops, including IκBα resynthesis and deubiquitinases such as A20, preventing excessive inflammation.
- NF-κB promotes cell survival by inducing anti-apoptotic proteins, which explains its central role in cancer and its cross-talk with the [Apoptosis Pathway](/knowledge/molecular-biology/apoptosis-pathway).
- Constitutive NF-κB activation drives many cancers and chronic inflammatory diseases, making it an important therapeutic target.
- Common experimental pitfalls include confusing canonical and non-canonical pathways, overlooking the transient nature of IκBα degradation, and failing to control for LPS contamination or overexpression artifacts.

## Further Reading

- Zusso M et al. *Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway*. Journal of neuroinflammation. 2019. [PubMed 31319868](https://doi.org/10.1186/s12974-019-1538-9)
- Blaj LA et al. *The Role of the NF-kB Pathway in Intracranial Aneurysms*. Brain sciences. 2023. [PubMed 38137108](https://doi.org/10.3390/brainsci13121660)
- Khongthong P, Roseweir AK, Edwards J. *The NF-KB pathway and endocrine therapy resistance in breast cancer*. Endocrine-related cancer. 2019. [PubMed 32013374](https://doi.org/10.1530/ERC-19-0087)
- Ibrahim S et al. *PIK3R3 regulates ZO-1 expression through the NF-kB pathway in inflammatory bowel disease*. International immunopharmacology. 2020. [PubMed 32473571](https://doi.org/10.1016/j.intimp.2020.106610)
- Pisani LF et al. *NF-kB pathway is involved in microscopic colitis pathogenesis*. The Journal of international medical research. 2022. [PubMed 35301900](https://doi.org/10.1177/03000605221080104)
- Cui C et al. *Air toxins disorder the NF-kB Pathway leads to immune disorders and immune diseases in the human health*. Ecotoxicology and environmental safety. 2025. [PubMed 40532606](https://doi.org/10.1016/j.ecoenv.2025.118474)

## Related Clinical & Scientific Guides

* [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway)
* [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor)
* [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)